Dr. Yuri Fesko of Quest Diagnostics says the "pathways approach" helped one health system speed the time between diagnosis and targeted treatment for lung cancer by as much as a month for some patients. This is the second part of a three-part video series.
Editor of Managed Healthcare Executive, Briana Contreras, speaks with Oncologist and Vice President of Medical Affairs at Quest Diagnostics, Dr. Yuri Fesko, about why shortening the gap of time it takes to receive a cancer diagnosis and getting the treatment for it is critical to ensuring better patient outcomes. Dr. Fesko also shared steps hospitals, health systems and physicians can take now to reduce testing delays, improve outcomes and lower costs of care. These steps include using an innovative “pathways” approach that helped one health system speed the time between diagnosis and targeted treatment for lung cancer by as much as a month for some patients.
FDA Sets Review Date for Datopotamab Deruxtecan in Breast Cancer
April 2nd 2024Datopotamab deruxtecan, which is being reviewed to treat adults with HR-positive, HER2-negative breast cancer, has an FDA target date in the first quarter of 2025. Datopotamab deruxtecan also is under FDA review for non-small cell lung cancer.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
Housing Linked to Lower Cancer Mortality Among U.S. Veterans
February 8th 2024A study published in Health Affairs shows that lung and colorectal cancer mortality was higher among veterans who were unhoused compared with those who were housed and higher yet in those who lost housing after they received a diagnosis.
Read More